Summary The in vivo antitumour activities of recombinant human interleukin-2 (rHIL-2) and recombinant human hybrid interferon alpha A/D (rIFN-aA/D) were tested in r'elation to adenocarcinoma 755. The tumour growth, following s.c. inoculation of tumour cells, was inhibited to a greater extent in mice treated with the combination of cytokines than in mice treated with either one alone. Pretreatment with these cytokines did not affect the tumour growth. Injection of tumour-bearing mice with a combination of these cytokines resulted in a marked increase in the total number of lymphocytes in the peritoneal cavity. Among them, Lyt-2+/L3T4-and asialo GM' cells were markedly enhanced by the combination of cytokines, and the frequencies of these marker cells were closely correlated with the antitumour activity. In tumour-bearing mice, the size of the thymus was decreased while that of the spleen was increased compared to non-tumour-bearing (normal) mice. Treatment with rHIL-2 caused the thymus, spleen and liver to be larger compared to untreated tumour-bearing mice, but when treated with a combination of rHIL-2 and rIFN-aA/D these organs were smaller than when rHIL-2 was administered alone. Thymocytes were drastically changed when mice were bearing a tumour or were treated with a cytokine. Especially immature T-cells, Lyt-2+/L3T4+, were drastically decreased in tumour-bearing mice, but were maintained following administration of rHIL-2 or rIFN-aA/D. When treated with rHIL-2 plus rIFN-aA/D, Lyt-2+/L3T4+ T-cells were decreased while Lyt-2+/ L3T4-T-cells were increased. Frequency of immature T-cells, Lyt-2-/L3T4-, was not changed. On the other hand, T-cell subsets of splenocytes were markedly decreased in tumour-bearing mice compared to normal mice, but all the subsets of splenocytes were almost unchanged even when tumour-bearing mice were treated with rHIL-2 plus rIFN-aA/D. Thus, injection of rHIL-2 and rIFN-aA/D to tumour-bearing mice resulted in induction of Lyt-2+/L3T4-and asialo GM1 + cells in the peritoneal cavity, and the frequencies correlated with the observed antitumour activity in vivo in this murine model. The increase in Lyt-2+/L3T4-T-cells in the peritoneal cavity may be related to changes in the T-cells in thymus.
IL-2 promotes in vitro growth of mature T-lymphocyte (Morgan et al., 1976; Smith, 1980) . The proliferation results from interaction with a specific cell membrane receptor (IL-2R), which is absent from resting T-cells (Hardt et al., 1987) . The thymus is regarded as the primary site for differentiation of T-lymphocytes (Metcalf, 1966) . However, the majority of in vivo activated T-cells in the thymus do not express IL-2R (Ceredig et al., 1985; Lugo et al., 1985) . Moreover, injection of IL-2 in vivo does not induce proliferation of mature Tlymphocytes but increases production of haemopoietic and NK cells (Piguet et al., 1986) .
Combination therapy with human recombinant IL-2 (rHIL-2) and human recombinant interferon-aA/D (rIFN- ocA/D) or murine recombinant interferon-fl (rIFN-f) produces marked retardation of tumour growth, and repeated treatment can lead to cure (Iigo et al., 1986 (Iigo et al., , 1988 Brunda et al., 1987) . In animals treated in vivo with antiasialo GM1 antibody or in NK-deficient beige mice, the potentiation did not decrease (Iigo et al., 1986 (Iigo et al., , 1988 . However, the tumour inoculated in athymic mice is not caused to regress by the combination of rHIL-2 and rIFN (ligo et al., 1986) , suggesting that the mechanism of tumour regression caused by combination of rHIL-2 and rIFN appears to involve T-cell maturation. T-lymphocytes were characterised by using the subsets of Lyt-2 and L3T4, and then we examined the subsets of lymphocytes in the peritoneal cavity, thymus and spleen of tumour-bearing mice after repeated injection with rHIL-2 and/or rIFN-aA/D by flow cytometry. We also examined for correlations between the subsets and the antitumour activity. Laboratory Animal Centre (Hamamatsu, Japan). Each group consisted of 6-8 mice. These were maintained under specificpathogen-free conditions in our laboratory. All experiments were initiated when the mice were 7 weeks old. However, combined treatment of mice with rHIL-2 and rIFN-aA/D, both cytokines injected i.p. or s.c., resulted in a substantial reduction in tumour size, but when one cytokine was injected i.p. and the other s.c., the potency of synergism became weaker (Table I) . Thus, when the combination of rHIL-2 and rIFN-axA/D was simultaneously injected to tumour-bearing mice, marked regression of the tumour was produced. However, when normal mice were pretreated with rHIL-2 plus rIFN-oaA/D for 8 days and then the tumour cells were inoculated on day 9, the tumour growth was not affected by any of the treatments. Therefore, we investigated lymphocytes in tumour-bearing mice.
Effect of combination of rHIL-2 and rIFN-axA/D on thymus, spleen and liver
The combination of cytokines markedly inhibited tumour growth. At that time, we first measured the organ weights to see the effects of the cytokines on the lymphoid organs: the thymus, spleen and liver. The thymus of the tumour-bearing mice (day 15) was markedly smaller than that of normal mice. When rHIL-2 was administered to tumour-bearing mice, the thymus was significantly larger than in untreated tumour-bearing mice. However, when the cytokines were combined, the thymus became significantly smaller than with rHIL-2 alone (Table II) . On the other hand, the spleen of tumour-bearing mice was markedly larger than in normal mice. Moreover, after rHIL-2 treatment the spleen was larger than in untreated tumour-bearing mice, but after the combination of rHIL-2 and rIFN-oaA/D the spleen was significantly smaller than with rHIL-2 alone. Furthermore, the liver weight after treatment with these cytokines was affected similarly to the spleen. Thus, the thymus, spleen and liver weights were affected by treatment with the cytokines, and there were marked differences between use of one cytokine alone and use of a combination of the cytokines. Changes in lymphocyte subsets in peritoneal cavity of tumour-bearing mice after treatment with rHIL-2 and rIFN-axA/D In vivo studies (Iigo et al., 1986 (Iigo et al., , 1988 suggest that one of the effector cells causing regression of the tumour is cytotoxic T-lymphocytes (CTL). In in vitro study, there is no difference in the augmentation of cytokine activity against YAC-1 in the splenic effector cells between treatment with rHIL-2 alone and combination of rHIL-2 and rIFN (ligo et al., 1988) . We then studied the T-cell subsets in lymphoid organs following administration of cytokines. Lymphocytes possess Lyt-antigenic phenotypes which are characteristic of helper T-cells (Lyt-2-/L3T4+) and CTL (Lyt-2+/L3T4-).
Lyt-antigenic phenotypes could therefore be of use in characterising the effector-cell for rHIL-2 and rIFN. First, we studied whether the lymphocytes in the peritoneal cavity were increased and their phenotypes were changed following treatment with cytokines by i.p. or s.c. flow cytometric analysis of responding lymphocytes in the peritoneal cavity tested for the presence of specific lymphocyte subpopulations defined by the monoclonal antibodies Thy-1.2, Lyt-1, L3T4, Lyt-2, Mac-1, asialo GM1 and Ia. There were marked differences between non-tumour-bearing (normal) and tumour-bearing mice; the frequencies of Lyt-l + and Lyt-2+ cells in tumour-bearing mice were higher than in normal mice, but Mac-i + and asialo GM1 + and Ta+ cells were less than in normal mice (Table III) . The total cell number of Tcells (Thy-1.2+, Lyt-l +, L3T4+, Lyt-2+) in tumour-bearing mice was markedly increased compared to normal mice. When rHIL-2 was administered to tumour-bearing mice, the total lymphocytes were increased and the frequencies (%) of Thy-1.2+, L3T4+, Lyt-2+, Mac-I+, asialo GM,+ and Ia+ marker cells were markedly increased. Total lymphocytes following rIFN-aA/D were not increased compared to tumour-bearing mice, but frequencies of Thy-1.2+ and asialo GM1 + marker cells were markedly increased. Total lymphocytes following administration of rHIL-2 plus rIFN-ocA/D (except for the combination of s.c. rHIL-2 and s.c. rIFNaA/D) were markedly increased (about 3-fold compared to tumour-bearing mice), and the frequencies of Thy-1.2+, Lyti+, L3T4+, Lyt-2+, Mac-I+ and asialo GM1 + cells were markedly increased. In particular the combination of rHIL-2 and rIFN-ocA/D increased the percentage of cells expressing the Lyt-2+ marker from 12 to 40%, in contrast to the frequency of Ta + cells, which are thought of as B cell markers, which was decreased by this combination. The frequency of Lyt-2+/L3T4+ cells in the peritoneal cavity was less than 1.5%. Moreover, the antitumour activity of cytokines correlated closely with the frequency (%) of Lyt-2+ cells (r=0.91, P<0.01) and asialo GM1 + cells (r=0.944, P<0.0 1).
Effect of rHIL-2 and rIFN-cxA/D on lymphocyte subsets of thymus and spleen The splenic and thymic reactions, following treatments with cytokines, in tumour-bearing mice was studied. The thymus is regarded as the differentiation site for T-cell lymphopoiesis. Almost all thymocytes (more than 99%) in normal mice were Thy-1.2+ cells, a major subpopulation was Lyt-2+/L3T4+ cells ( Figure 1 ) and a small subpopulation comprising 2-3% of cells expressed neither Lyt-2 nor L3T4 (Lyt-2-/L3T4-), which has been proposed as a putative Tcell precursor (Mathieson et al., 1984; Ceredig et al., 1985 On the other hand, all the T-cell surface markers of splenocytes in the tumour-bearing mice were decreased compared to normal mice, and only asialo GM1 marker cells were increased. There were no marked differences in surface markers between treatment with cytokine alone and their combination (Figure 2 ).
L3T4+ cells (22 vs 40%

Discussion
Combination of rHIL-2 and rIFN-aA/D markedly enhances the antitumour effect compared to cytokine alone, and repeated treatment results in some cases of cure in mice (Iigo et al., 1988) . This enhanced antitumour effect is not reduced in animals treated in vivo with anti-asialo GM1 antibody or in NK-deficient beige mice (ligo et al., 1986, 1988 (day 15) became too small and spleen too large. When rHIL-2 was administered to tumour-bearing mice, the weights of the thymus, spleen and liver became significantly higher than in untreated tumour-bearing mice. When rHIL-2: was administered together with rIFN-aA/D, the thymus, spleen and liver weight became smaller than when rHIL-2 was administered alone. These phenomena indicate that cytokines directly or indirectly affect these lymphoid organs. rHIL-2 potentiates both the growth and cytotoxic function of T-lymphocytes and NK cells (Lanier et al., 1988) . However, Piguet et al. (1986) reported that rHIL-2 treatment in vivo did not induce proliferation of mature T-lymphocytes. IFN can act as a CTL differentiation signal (Chen et al., 1986) . The count of lymphocytes in the peritoneal cavity was (Piguet et al., 1986) . The host defence mechanism in the presence of a tumour may be responsible for augmentation of the frequencies of Tcells because Lyt-2-/L3T4+ (helper) and Lyt-2+/L3T4-(CTL) were increased in thymus of tumour-bearing mice. Although the pathway by which helper T-cells and CTL develop from immature precursors within the thymus is largely obscure, treatment with cytokines markedly changed the T-cell markers. rHIL-2 or rIFN-aA/D maintained large percentages of Lyt-2+/L3T4+ immature T-cells in the thymus without any effect of tumour-bearing, but immature Lyt-2-/L3T4-T-cells were not increased. In the case of combination of rHIL-2 and rIFN-aA/D, Lyt-2+/L3T4+ cells were decreased and Lyt-2+/L3T4-cells were increased similar to the lymphocytes in the peritoneal cavity. Thus, the frequency of Lyt-2+/L3T4+ immature T-cells was more than 90% in the thymus of normal mice but only 20% in tumourbearing mice (advanced tumour). If rHIL-2 or rIFN-aA/D was injected into tumour-bearing mice, Lyt-2+/L3T4+ cells were 40-50%, but if rHIL-2 was injected together with rIFN-aA/D, Lyt-2+/L3T4+ cells were drastically decreased to 2-10%. This evidence suggests that Lyt-2+/L3T4+ immature T-cells may be important to generate mature Lyt-2+ cells. It is known that Lyt-2-/L3T4-T-cells are important to produce mature T-cells (Raulet, 1985; Lowenthal et al., 1988) . Maybe the combination of rHIL-2 and rIFN-aA/D promotes formation of mature Tlymphocytes (Lyt-2+/L3T4-) from immature Tlymphocytes (Lyt-2-/L3T4-) in the thymus.
Recently, Brunda et al., (1987) reported that the combination of rHIL-2 and rIFN-aA/D showed a synergic antitumour effect by the induction of an NK-cell-like population. Cameron et al. (1988) reported that the combination of rHIL-2 and rIFN-aA/D showed significant reductions in the number of MCA-106 liver metastases compared to cytokine alone also reported that this synergy was dependent on Lyt-2+ T-cells.
Although we have no evidence of NK cells being responsible for the regression of tumours, combined treatment with rHIL-2 and rIFN can induce large numbers of Lyt-2+/L3T4-and asialo GM1 + cells. The enhanced antitumour effect may be due to an increase in the number of active Lyt-2+/L3T4-and asialo GM1 + cells at the tumour site.
